[1] KAPURIA D,TAKYAR V K,ETZION O, et al. Association of hepatic steatosis with subclinical atherosclerosis:systematic review and Meta-analysis[J]. Hepatol Commun, 2018,2(8):873-883. [2] GAO S,ZHAO D,WANG M, et al. Association between circulating oxidized LDL and atherosclerotic cardiovascular disease:A Meta-analysis of observational studies[J]. Can J Cardiol, 2017,33(12):1624-1632. [3] FADAEI R,POUSTCHI H,MESHKANI R, et al. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis[J]. Sci Rep, 2018,8(1):11691. [4] KYPREOS K E,GKIZAS S,RALLIDIS L S, et al. HDL particle functionality as a primary pharmacological target for HDL-based therapies[J]. Biochem Pharmacol, 2013,85(11):1575-1578. [5] MORA S,GLYNN R J,RIDKER P M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy[J]. Circulation, 2013,128(11):1189-1197. [6] WANGY,NⅡMIM,NISHIJIMAK, et al.Human Apolipoprotein A-Ⅱ protects against diet-Induced atherosclerosis in transgenic rabbits[J]. Arterioscler Thromb Vasc Biol, 2013,33(2):224-231. [7] ROSENSON R S,BREWER HB,DAVIDSON W S, et al. Cholesterol efflux and atheroprotection:advancing the concept of reverse cholesterol transport[J]. Circulation, 2012, 125(15):1905-1919. [8] COOKE A L,MORRIS J,MELCHIOR J T, et al. A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL[J]. J Lipid Res, 2018,59(7):1244-1255. [9] UCHIDA S,DIMMELER S. Long noncoding RNAs in cardiovascular diseases[J]. Circ Res,2015,116(4):737-750. [10] HALLEY P,KADAKKUZHA B M,FAGHIHI M A, et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA[J]. Cell Rep, 2014, 6(1):222-230. [11] COVEY S D,KRIEGER M,WANG W,et al. Scavenger receptor class B type Ⅰ-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells[J]. Arterioscler Thromb Vasc Biol, 2003, 23(9):1589-1594. [12] RUBIN E M,KRAUSS R M,SPANGLER E A, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI[J]. Nature, 1991, 353(6341):265-267. [13] ZHANG Y,ZANOTTI I,REILLY M P, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo[J]. Circulation, 2003,108(6):661-663. [14] DUVERGER N,KRUTH H,EMMANUEL F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits[J]. Circulation, 1996, 94(4):713-717. [15] IKENAGA M,HIGAKI Y,SAKU K, et al. High-density lipoprotein mimetics:a therapeutic tool for atherosclerotic diseases[J]. J Atheroscler Thromb, 2016, 23(4):385-394. [16] FAGHIHI M A,WAHLESTEDT C. Regulatory roles of natural antisense transcripts[J]. Nat Rev Mol Cell Biol, 2009, 10(9):637-643. [17] WAHLESTEDT C. Natural antisense and noncoding RNA transcripts as potential drug targets[J].Drug Discov Today, 2006, 11(11/12):503-508. [18] LEHNER B,WILLIAMS G,CAMPBELL R D, et al. Antisense transcripts in the human genome[J]. Trends Genet, 2002, 18(2):63-65. [19] 张鹏, 王艳丽, 郭世文,等. 家兔胆固醇酯转移蛋白基因克隆及其真核表达载体的构建[J]. 吉林大学学报:医学版,2013,39(4):837-840. [20] SHRESTHA S,WU B J,GUINEY L, et al. Cholesteryl ester transfer protein and its inhibitors[J]. J Lipid Res,2018,59(5):772-783. |